No Data
No Data
Express News | Merck: Will Continue Discussions With FDA to Help Enable Continued Access to Keytruda for Appropriate Patients
Express News | Merck Provides Update on Fda’s Oncologic Drugs Advisory Committee Meeting Discussion of Pd-L1 Expression Levels in Certain Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer Indications
Merck, Bristol-Myers Fail to Convince FDA AdCom on Wider Opdivo, Keytruda Use
Is Merck & Co., Inc. (MRK) the Best Cheap Beginner Stock to Invest In?
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
Evaxion Stock Jumps on Expanded Vaccine Development Pact With MSD
No Data
No Data
ひな☆彡 SOXL : You convinced me. I am happy to buy some later.
Growth Investor27 : Long ESPR $1.61 is very cheap.
Growth Investor27 : Long150,000 will hold for 5x upside for 2025 if not aquired.